enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)
Gigante P, Berni M, Bussolati S, Grasselli F, Grolli S, Ramoni R, et al
RinninellaERaoulPCintoniMFranceschiFMiggianoGADGasbarriniAet alWhat is the healthy gut Microbiota composition
With or without food: Both can be taken with or without food, though some users prefer taking Heat on an empty stomach for more pronounced thermogenic sensations
The GLP-1 medication semaglutide has been shown to be effective and safe across a broad population of people with overweight and obesity, leading to 10-20% weight loss which is usually needed to see the benefits
